The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2022 | Selecting frontline treatments strategies & monitoring patients with multiple myeloma
Meral Beksac, MD, Ankara University, Ankara, Turkey, talks on improving the outcomes of patients with multiple myeloma, highlighting the importance of selecting the best frontline treatment regimen in patients with multiple myeloma. Dr Beksac explains that the initial treatment a patient receives will determine the maximum treatment response they are able to achieve. It is also important to carefully monitor patients for M protein and serum free light chain levels, as well as extramedullary disease and resistant clones. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
